Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bugs As Drugs: The Budding Microbiome Modulator Pipeline

Executive Summary

INFOGRAPHIC: The sheer number of micro-organisms in the human body and their functions makes the microbiome a ripe target for therapeutic intervention. While still rather early, data show the microbiome modulator pipeline has immense potential across a range of therapeutic areas, not just in gastrointestinal disease.

You may also be interested in...



AOBiome Targets Atopic Dermatitis Niche With Bacteria-Based Drug

While the atopic dermatitis market overall is crowded, the company sees a market opportunity for a drug that addresses both appearance and itching, as well as having favorable safety and ease of use.

‘Bugs As Drugs’ Approach To Cancer Nears Advanced Development

Microbiome modulators, known mainly for development in infectious and gastrointestinal diseases, could prove an asset in oncology thanks to the work of biotechs.

Lundbeck And Axsome Rival Candidate Data Raise Prospects For First Alzheimer’s Agitation Approvals

The firms unveiled positive Phase III data from their respective assets for treating the agitation seen in Alzheimer’s disease with Lundbeck’s candidate set to become first-to-market for the challenging behavioral symptom.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC145790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel